openPR Logo
Press release

Bag3-related Gene Therapies Market Forecast 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

08-05-2025 07:32 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Bag3-related Gene Therapies Market

Bag3-related Gene Therapies Market

DelveInsight's "Bag3-related Gene Therapies Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Bag3-related Gene Therapies, historical and forecasted epidemiology as well as the Bag3-related Gene Therapies market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report offers a detailed examination of Bag3-related Gene Therapies, presenting valuable insights into revenue trends, disease prevalence, and the current treatment landscape. It explores essential statistics, including both current and anticipated market size, while assessing the effectiveness and progress of new therapeutic developments. The report also reviews the clinical trial landscape, highlighting ongoing and upcoming studies that are expected to influence the future of Bag3-related Gene Therapies. This comprehensive resource is crucial for understanding market dynamics and the evolving therapeutic approaches within this field.

To Know in detail about the Bag3-related Gene Therapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bag3-related Gene Therapies Market Forecast - https://www.delveinsight.com/sample-request/bag3-related-gene-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Bag3-related Gene Therapies Market Report:
• The Bag3-related Gene Therapies market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In April 2025, Affinia Therapeutics, a pioneering gene therapy company developing first- or best-in-class adeno-associated virus (AAV) therapies for severe cardiovascular and neurological disorders, announced that new preclinical findings on AFTX-201 (its lead program for BAG3 dilated cardiomyopathy), along with data on its novel AAV capsids targeting central nervous system (CNS) diseases and its high-yield manufacturing process, will be showcased in multiple oral and poster presentations at the 28th Annual American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting.
• In January 2025, Affinia Therapeutics, a cutting-edge gene therapy company focused on adeno-associated virus (AAV) therapies for severe cardiovascular and neurological diseases, has announced AFTX-201 as its lead development candidate for treating BAG3 dilated cardiomyopathy (DCM). Designed as a potential best-in-class gene therapy delivered through a single intravenous (IV) injection, AFTX-201 is currently in IND-enabling studies. Affinia successfully completed a pre-IND meeting with the U.S. FDA in late 2024 and plans to submit an IND application in the fourth quarter of 2025.
• In January 2024, Solid Biosciences is preparing to conduct biodistribution and preclinical studies of AVB-401 for BAG3 in mice and non-human primates.
• Key Bag3-related Gene Therapies Companies: Rocket Pharmaceuticals, Solid Biosciences, and others
• Key Bag3-related Gene Therapies Therapies: AAV BAG3-DCM/ REN-001, AVB-401, and others
• The Bag3-related Gene Therapies market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bag3-related Gene Therapies pipeline products will significantly revolutionize the Bag3-related Gene Therapies market dynamics.
• Cardiomyopathy is frequently undiagnosed, so prevalence estimates may differ. It is believed that up to 1 in 500 adults could be affected. This condition can occur in males and females of any age and ethnicity.
• As reported by Ababio et al. (2022), the prevalence of idiopathic dilated cardiomyopathy (DCM) in the United States was estimated at 59.23 cases per 100,000 individuals.
• A study by Dominguez et al. (2018) estimated that around 2-4% of dilated cardiomyopathy cases are attributed to BAG3 mutations. It is projected that there are nearly 29,000 cases in the United States and approximately 33,000 patients in Europe.

Bag3-related Gene Therapies Overview
Bcl-2-associated athanogene 3 (Bag3) is a co-chaperone protein involved in various cellular processes, including apoptosis, autophagy, and cytoskeletal organization. Mutations or dysregulation of the BAG3 gene are implicated in several disorders, particularly dilated cardiomyopathy (DCM), myofibrillar myopathy, and certain cancers. In recent years, gene therapies targeting BAG3-related diseases have garnered significant interest, especially for inherited cardiomyopathies.

Gene therapy approaches for BAG3-related conditions primarily aim to restore or enhance Bag3 function using adeno-associated virus (AAV)-based delivery systems. AAV9 vectors have shown promise in preclinical models by delivering functional BAG3 copies directly to cardiomyocytes, thereby improving cardiac contractility, reducing fibrosis, and increasing survival. One such investigational therapy is RT-100, developed by Renovacor (now part of Rocket Pharmaceuticals), targeting BAG3-mutant DCM.

Beyond cardiomyopathies, modulation of BAG3 expression is also being explored in oncology and neurodegeneration, where its role in autophagy and cell survival is critical. However, the challenge lies in tissue-specific delivery and balancing Bag3's protective and pro-survival roles, especially in cancer.

Overall, BAG3-focused gene therapies represent a promising frontier in precision medicine, with ongoing research seeking to translate early-stage findings into effective clinical interventions for rare but severe genetic diseases.

Get a Free sample for the Bag3-related Gene Therapies Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/bag3-related-gene-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Bag3-related Gene Therapies Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bag3-related Gene Therapies Epidemiology Segmentation:
The Bag3-related Gene Therapies market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Bag3-related Gene Therapies
• Prevalent Cases of Bag3-related Gene Therapies by severity
• Gender-specific Prevalence of Bag3-related Gene Therapies
• Diagnosed Cases of Episodic and Chronic Bag3-related Gene Therapies

Download the report to understand which factors are driving Bag3-related Gene Therapies epidemiology trends @ Bag3-related Gene Therapies Epidemiology Forecast - https://www.delveinsight.com/sample-request/bag3-related-gene-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Bag3-related Gene Therapies Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bag3-related Gene Therapies market or expected to get launched during the study period. The analysis covers Bag3-related Gene Therapies market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bag3-related Gene Therapies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bag3-related Gene Therapies Therapies and Key Companies
• AAV BAG3-DCM/ REN-001: Rocket Pharmaceuticals
• AVB-401: Solid Biosciences

Discover more about therapies set to grab major Bag3-related Gene Therapies market share @ Bag3-related Gene Therapies Treatment Landscape
https://www.delveinsight.com/sample-request/bag3-related-gene-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Bag3-related Gene Therapies Market Strengths
• Heart diseases have a high prevalent pool and are chronic in nature which might a reason why key companies are targeting BAG3 related DCM and there is a possibility that they might get a first mover advantage
• Understanding BAG3 variations could lead to tailored treatments based on genetic profiles

Bag3-related Gene Therapies Market Opportunities
• Since no therapies are approved for BAG3 related gene thrapies, there is a significant market opportunity for the companies to enter this space and get the first-mover advantage

Scope of the Bag3-related Gene Therapies Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bag3-related Gene Therapies Companies: Rocket Pharmaceuticals, Solid Biosciences, and others
• Key Bag3-related Gene Therapies Therapies: AAV BAG3-DCM/ REN-001, AVB-401, and others
• Bag3-related Gene Therapies Therapeutic Assessment: Bag3-related Gene Therapies current marketed and Bag3-related Gene Therapies emerging therapies
• Bag3-related Gene Therapies Market Dynamics: Bag3-related Gene Therapies market drivers and Bag3-related Gene Therapies market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bag3-related Gene Therapies Unmet Needs, KOL's views, Analyst's views, Bag3-related Gene Therapies Market Access and Reimbursement

To know more about Bag3-related Gene Therapies companies working in the treatment market, visit @ Bag3-related Gene Therapies Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/bag3-related-gene-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Bag3-related Gene Therapies Market Report Introduction
2. Executive Summary for Bag3-related Gene Therapies
3. SWOT analysis of Bag3-related Gene Therapies
4. Bag3-related Gene Therapies Patient Share (%) Overview at a Glance
5. Bag3-related Gene Therapies Market Overview at a Glance
6. Bag3-related Gene Therapies Disease Background and Overview
7. Bag3-related Gene Therapies Epidemiology and Patient Population
8. Country-Specific Patient Population of Bag3-related Gene Therapies
9. Bag3-related Gene Therapies Current Treatment and Medical Practices
10. Bag3-related Gene Therapies Unmet Needs
11. Bag3-related Gene Therapies Emerging Therapies
12. Bag3-related Gene Therapies Market Outlook
13. Country-Wise Bag3-related Gene Therapies Market Analysis (2019-2032)
14. Bag3-related Gene Therapies Market Access and Reimbursement of Therapies
15. Bag3-related Gene Therapies Market Drivers
16. Bag3-related Gene Therapies Market Barriers
17. Bag3-related Gene Therapies Appendix
18. Bag3-related Gene Therapies Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bag3-related Gene Therapies Market Forecast 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight here

News-ID: 4134104 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Therapies

GM1 Gangliosidosis Market: Epidemiology, Therapies, Companies, DelveInsight | Pa …
GM1 Gangliosidosis therapies, such as PBGM01, and others, are expected to boost the GM1 Gangliosidosis Market in the upcoming years. DelveInsight has launched a new report on "GM1 Gangliosidosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the GM1 Gangliosidosis, historical and forecasted epidemiology as well as the GM1 Gangliosidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover
Facioscapulohumeral Muscular Dystrophy Pipeline Assessment 2024: Therapies, Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Facioscapulohumeral Muscular Dystrophy pipeline constitutes 10+ key companies continuously working towards developing 10+ Facioscapulohumeral Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Facioscapulohumeral Muscular Dystrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Facioscapulohumeral Muscular
Intratumoral Cancer Therapies Market Report 2024 - Intratumoral Cancer Therapies …
"The Business Research Company recently released a comprehensive report on the Global Intratumoral Cancer Therapies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The intratumoral cancer therapies
Innovative Therapies in Alcohol Rehabilitation
Alcohol rehabilitation has evolved significantly over the years, with innovative therapies emerging as crucial elements in the journey to recovery. These groundbreaking approaches go beyond traditional methods, providing individuals struggling with alcohol addiction with a diverse set of tools to achieve and maintain sobriety. In this article, we delve into innovative therapies, exploring their effectiveness and impact on alcohol rehabilitation if you'd like to know more about alcohol rehab in
B-cell Maturation Antigen (BCMA) Targeted Therapies Market New Development of No …
A global prevalence of over one million cases. B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen targeted therapy for the treatment of multiple myeloma. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies,
Viral Vector Contract Manufacturing Market Outlook 2021- Gene Therapies, Cell Th …
The latest report released on Outlook for Viral Vector Contract Manufacturing - Gene Therapies, Cell Therapies, and COVID-19 Vaccines Market analyses areas where there is still room for improvement. Irrespective of industry, organization size or geographic location, the Outlook for Viral Vector Contract Manufacturing - Gene Therapies, Cell Therapies, and COVID-19 Vaccines Market study suggests that advanced technologies are playing a bigger role than ever before. The assessment provides trend,